Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multipl...
Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical ...
Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multiple myeloma ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )
25 Sep 2019
PLEIADES: Daratumumab combinations for multiple myeloma
Dr Ajai Chari - Mount Sinai, New York City, USA
PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )
25 Sep 2019
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multipl...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multip...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
23 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Blinatumomab for relapsed/refractory Burkitt's lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019